U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H16ClNO3
Molecular Weight 257.713
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MECLOFENOXATE

SMILES

CN(C)CCOC(=O)COC1=CC=C(Cl)C=C1

InChI

InChIKey=XZTYGFHCIAKPGJ-UHFFFAOYSA-N
InChI=1S/C12H16ClNO3/c1-14(2)7-8-16-12(15)9-17-11-5-3-10(13)4-6-11/h3-6H,7-9H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C12H16ClNO3
Molecular Weight 257.713
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Meclofenoxate (INN, BAN) (brand name Lucidril), also known as centrophenoxine, is a cholinergic nootropic used as a dietary supplement and drug in the treatment of symptoms of senile dementia and Alzheimer's disease. Meclofenoxate has been shown in studies to be effective in enhancing the memory and in improving the cognitive functions of the elderly. Some studies even suggest that Meclofenoxate has the ability to reverse the signs of brain aging. While claims about its ability as a nootropic agent have not been fully established in clinical trials, some studies do strongly suggest that it is indeed very effective in improving memory retention and recall. Meclofenoxate HCL Powder for Injection is also indicated for the following conditions: comma; skull and brain trauma; following a stroke; encephalopathy; mental disorders (in combination with psychotropic agents); mental and psychomotor retardation in children; brain intoxication; alcohol psychoses; neuritis and polyneuritis. The main mechanism of action of Meclofenoxate is generally believed to be cholinergic in nature. As an efficient transporter of DMAE, Meclofenoxate encourages the production of choline in the brain, which is then synthesized into acetylcholine. The more acetylcholine neurotransmitters in the brain, the better and more efficient the cognitive functions will be. Meclofenoxate also increases cellular membrane phospholipids

CNS Activity

Originator

Approval Year

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Lucidril
Primary
Lucidril
Primary
Unknown

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Elderly people with significant intellectual decline may chose 3 to 6 Centrophenoxine tablets (250 mg) per day taken preferably with breakfast and lunch, in order to avoid insomnia. For the non-elderly wishing to utilize the brain boosting benefits of Centrophenoxine, perhaps only 1 or 2 Centrophenoxine tablets (250 mg each) daily with breakfast or lunch.
Route of Administration: Oral
In Vitro Use Guide
The superoxide radical scavenging ability of centrophenoxine (CPH/MECLOFENOXATE) was studied in vitro using the method of pyrogallol autoxidation, cytochrome c reduction and photoxidation of o-dianisidine in salt-free assay media and in the presence of increasing NaCl or KCl concentrations. The CPH proved to be a superoxide radical scavenger in all three systems used, however, the rate constant for this reaction was rather low (1.7 X 10(2) M-1 s-1).
Substance Class Chemical
Record UNII
C76QQ2I0RG
Record Status Validated (UNII)
Record Version